|
JP2019147806A
|
|
Pharmaceutical composition and kit
|
|
SG11201701028SA
|
|
Novel antibodies directed to fc gamma receptor iib and fc epsilon receptor
|
|
EP2740805A1
|
|
Stratification and treatment of patients suffering from idiopathic thrombocytopenic purpura
|
|
US2015274804A1
|
|
Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein
|
|
MX2015005266A
|
|
Fc gamma receptor iib variants.
|
|
WO2014067959A1
|
|
A pharmaceutical composition for use in treating or preventing either one or both of an inflammatory disease and an autoimmune disease
|
|
CA2927263A1
|
|
Soluble fc gamma receptor for treatment of autoimmune bullous diseases
|
|
EP2837637A1
|
|
Novel anti-FcyRIIB IgG-type antibody
|
|
EP2833139A1
|
|
In vitro method for determining the stability of compositions comprising soluble Fc gamma receptor(s)
|
|
EP2796144A1
|
|
Highly concentrated Formulations of soluble Fc receptors
|
|
KR20140055589A
|
|
A pharmaceutical composition for use in treating or preventing either one or both of an inflammatory disease and an autoimmune disease
|
|
CA2794719A1
|
|
A method for treating or preventing either one or both of an inflammatory disease and an autoimmune disease
|
|
AU2012244302A1
|
|
A method for treating or preventing either one or both of an inflammatory disease and an autoimmune disease
|
|
EP2161031A1
|
|
Fc gamma receptor for the treatment of B cell mediated multiple sclerosis
|
|
AU2007332085A1
|
|
Multimeric Fc receptor polypeptides including a modified Fc domain
|
|
BRPI0721078A2
|
|
MULTIMERIC Fc RECEIVER POLYPEPTIDES INCLUDING A MODIFIED Fc DOMAIN
|
|
US2008008700A1
|
|
Multimeric Fc receptor polypeptides
|
|
EP1870422A1
|
|
Means for the treatment of diseases characterized by an excessive immune reaction
|
